Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells

International Journal of Radiation Biology

Volumn 87, Issue 2, 2011, Pages 192-201

  Van Nifterik, Krista A ^a   Van Den Berg, Jaap ^a   Slotman, Ben J ^a   Van Rijn, Johannes ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

glioma cells; meloxicam; temozolomide; trimodal treatment; X rays

Indexed keywords

MELOXICAM; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CELL COUNT; CELL CYCLE PHASE; CELL POPULATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIZATION; X RAY;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL CYCLE; COMBINED MODALITY THERAPY; CYCLOOXYGENASE INHIBITORS; DACARBAZINE; GLIOMA; HUMANS; THIAZINES; THIAZOLES; TIME FACTORS; TUMOR CELLS, CULTURED; X-RAYS;

EID: 79551629840     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2010.519423     Document Type: Article

References (41)

1. Balmforth AJ, Ball SG, Freshney RI, Graham DI, McNamee HB, Vaughan PF. 1986. D-1 dopaminergic and beta-adrenergicstimulation of adenylate cyclise in a clone derived from the human astrocytoma cell line G-CCM. Journal of Neurochemistry 47:715-719.
2. Bijnsdorp IV, van den Berg J, Kuipers GK, Wedekind LE, Slotman BJ, van Rijn J, Lafleur MV, Sminia P. 2007. Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells. Journal of Neuro-Oncology 85:25-31.
3. Brennand J, Margison GP. 1986. Reduction of the toxicity and utagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene. Proceedings of the National Academy of Sciences of the USA 83:6292-6296.
4. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM, Loeffler JS. 2006. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clinical Cancer Research 12:4738-4746.
5. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, Jiricny J. 1998. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Molecular Pharmacology 54:334-341.
6. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. 2006. Clonogenic assay of cells in vitro. Nature Protocols 1:2315-2319.
7. Gerson SL. 2004. MGMT: Its role in cancer aetiology and cancer therapeutics. Nature Reviews Cancer 4:296-307.
8. Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G. 2001. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX- 2 inhibitor celecoxib. The FASEB Journal 15:2742-2744.
9. Hara A, Okayasu I. 2004. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: Correlation with angiogenesis and prognostic significance. Acta Neuropathologica 108:43-48.
10. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R. 2004. Clinical trial substantiates the predictive value of O-6- methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clinical Cancer Research 10:1871-1874.
11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England Journal of Medicine 352:997-1003.
12. Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO. 2003. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNAmethylating agents. Molecular and Cellular Biology 23:8306-8315.
13. Iwase N, Higuchi T, Gonda T, Kobayashi H, Uetake H, Enomoto M, Sugihara K. 2007. The effect of meloxicam, a selective COX-2 inhibitor, on the microvasculature of small metastatic liver tumors in rats. Japanese Journal of Clinical Oncology 37:673-678.
14. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, Seyfried NT, Abe T, Chen LB, Carroll RS, Black PM. 2000. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Research 60:4926-4931.
15. Kaina B, Ziouta A, Ochs K, Coquerelle T. 1997. Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex' and methylation-tolerant mismatch repair compromised cells: Facts and models. Mutation Research 381:227-241.
16. Kardosh A, Blumenthal M, Wang WJ, Chen TC, Schö nthal AH. 2004. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biology & Therapy 3:55-62.
17. Kern MA, Schö neweiss MM, Sahi D, Bahlo M, Haugg AM, Kasper HU, Dienes HP, Käferstein H, Breuhahn K, Schirmacher P. 2004. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 25:1193-1199.
18. Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, Camphausen K. 2008. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clinical Cancer Research 14:931-938.
19. Kuipers GK, Slotman BJ, Wedekind LE, Stoter TR, van den Berg J, Sminia P, Lafleur MV. 2007. Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: Independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. International Journal of Radiation Biology 83:677-685.
20. Mizutani Y, Nakanishi H, Li YN, Sato N, Kawauchi A, Miki T. 2004. Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. Journal of Urology 172:1474-1479.
21. Naruse T, Nishida Y, Hosono K, Ishiguro N. 2006. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 27:584-592.
22. Naruse T, Nishida Y, Ishiguro N. 2007. Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells. Biomedicine & Pharmacotherapy 61:338-346.
23. Owens RB, Smith HS, Nelson-Rees WA, Springer EL. 1976. Epithelial cell cultures from normal and cancerous human tissues. Journal of the National Cancer Institute 56:843-849.
24. Perdiki M, Korkolopoulou P, Thymara I, Agrogiannis G, Piperi C, Boviatsis E, Kotsiakis X, Angelidakis D, Diamantopoulou K, Thomas-Tsagli E, Patsouris E. 2007. Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Molecular and Cellular Biochemistry 295:75-83.
25. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ. 2000. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clinical Cancer Research 6:2513-2520.
26. Pontén J, Westermark B. 1978. Properties of human malignant glioma cells in vitro. Medical Biology 56:184-193.
27. Pyo H, Choy H, Amorino GP, Kim JS, Cao Q, Hercules SK, DuBois RN. 2001. A selective cyclooxygenase-2 inhibitor, NS- 398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clinical Cancer Research 7:2998-3005.
28. Raju U, Nakata E, Yang P, Newman RA, Ang KK, Milas L. 2002. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: Mechanistic considerations. International Journal of Radiation Oncology Biology Physics 54:886-894.
29. Scheda A, Finjap JK, Tuettenberg J, Brockmann MA, Hochhaus A, Hofheinz R, Lohr F, Wenz F. 2007. Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. Tumori 93:31-36.
30. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. 2001. Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Research 61:4375-4381.
31. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS. 2002. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. Journal of the National Cancer Institute 94:585-591.
32. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr, Chou TC. 1999. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Research 59:6178-6184.
33. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine 352:987-996.
34. Tegeder I, Pfeilschifter J, Geisslinger G. 2001. Cyclooxygenaseindependent actions of cyclooxygenase inhibitors. The FASEB Journal 15:2057-2072.
35. Van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MV, Leenstra S, Slotman BJ, Hulsebos TJ, Sminia P. 2007. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. International Journal of Radiation Oncology Biology Physics 69:1246-1253.
36. Van Nifterik KA, van den Berg J, van der MeideWF, Ameziane N, Wedekind LE, Steenbergen RD, Leenstra S, Lafleur MV, Slotman BJ, Stalpers LJ, Sminia P. 2010. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. British Journal of Cancer 103:29-35.
37. Van Rijn J, van den Berg J, Meijer OW. 1995. Proliferation and clonal survival of human lung cancer cells treated with fractionated irradiation in combination with paclitaxel. International Journal of Radiation Oncology Biology Physics 33:635-639.
38. Van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ. 2000. Survival of human glioma cells treated with various combination of temozolomide and X-rays. International Journal of Radiation Oncology Biology Physics 47:779-784.
39. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. 2002. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Research 62:2029-2033.
40. Wolfesberger B, Walter I, Hoelzl C, Thalhammer JG, Egerbacher M. 2006. Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Research in Veterinary Science 80:308-316.
41. Xin B, Yokoyama Y, Shigeto T, FutagamiM,Mizunuma H. 2007. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer 110:791-800.